Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Incyte

Incyte/Merck trial failure bodes ill for IDO class

Incyte/Merck trial failure bodes ill for IDO class

Incyte/Merck trial failure bodes ill for IDO class. The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone. ... Ahead of the weekend, Incyte and partner Merck &Co were rocked by the news that their much-touted

Sanofi’s PD-1 inhibitor starts EU review for skin cancer

Sanofi’s PD-1 inhibitor starts EU review for skin cancer In addition to chasing companies in the category with already-marketed drugs - which also include Roche, AstraZeneca and Merck KGaA/Pfizer - Novartis’PDR001 and INCSHR-1210 from Incyte/Jiangsu Hengrui are

Deal Watch January 2018

Option, collaboration. 1, 063. Syros Pharmaceuticals/ Incyte. Gene control platform to identify up to seven therapeutic targets with a focus in myeloproliferative neoplasms.

Celgene boosts haematology pipeline with $7bn Impact Bio deal

Celgene boosts haematology pipeline with $7bn Impact Bio deal to Incyte and Novartis’rival JAK inhibitor Jakafi (ruxolitinib), which grew 35% to $831m in the first nine months of 2017.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics